Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10506 in Hepatic Impairment
NCT07844967Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-10506 (4 cohorts), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
HS-10506
Beyond the preview
Go deeper on NCT07844967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07844967.